Dear Colleagues, 

The close of the fiscal year presents an appropriate time to evaluate the performance of the campus in terms of technology transfer and industry sponsored research.

I am delighted to announce a record 406 inventions were reported to OIP-ISR during fiscal year 2013, representing a 14% increase over 2012. We greatly appreciate the effort on the part of UCLA’s faculty, staff and students in disclosing these innovations to our office. This number reflects the world-class research being conducted across the entire campus and we expect this upward trend to continue.

Gross licensing revenues for fiscal year 2013 totaled $23M, up from $18M in 2012. We anticipate this number to increase following the launch last September of Xtandi®, a prostate cancer drug developed by researchers at UCLA. Industry Sponsored Research awards remained level at $39M, but constituted an overall increase in the percentage of research support coming from industry.

The campus has garnered national recognition for its success in new company formation, with 18 startup companies recorded for fiscal year 2013. OIP-ISR continues to foster the development of an entrepreneurial environment on-campus, as exemplified by the creation of a dedicated business development team and the introduction of an entrepreneurs-in residence program. More details on these and other activities can be found on our website.

We will be striving to build upon the success in the coming fiscal year and look forward to working with you to develop UCLA technologies into new products and services that broadly benefit the public.

Sincerely,

Brendan Rauw 
Associate Vice Chancellor and Executive Director of Entrepreneurship

Few, if any, programs have led to as many spin-off and commercial licenses

"UCLA's world-class research in prostate cancer, joined with over 15 years of faculty entrepreneurial initiative and technology transfer efforts, are bringing life-saving technology to the clinic and the marketplace," said Emily Loughran, director of licensing in UCLA’s Office of Intellectual Property and Industry Sponsored Research. "It is truly gratifying to see a lot of hard work come to fruition..."

[ Read More ]

Academic Spinouts - LA Business Journal Special Report
Report highlights examples of companies that spun off from university labs.

"Examples of success stories from UCLA include: Lyxia Corp., which uses algae to produce oil; ImaginAb Inc. is a medical imaging company that helps oncologists make better diagnoses; and  Armagen Technologies Inc. researches treatments for diseases that affect the brain and central nervous system..."

[ Read More (LABJ subscription required)]

The award brings Tunitas' NIH-led grant funding to nearly $10 million.

The three-year, $3 million grant is aimed at advancing Tunitas' first clinical candidate, a member of the GE2 family, into preclinical development..."

[ Read More ]

The Company is planning to conduct a multi-center trial at leading medical institutions in the U.S., Europe and Canada.

The objective of the study is to evaluate the safety and effectiveness of the device and provide the basis for a Pre‐Market Approval (PMA) application to the FDA..."

[ Read More ]

UCLA Invents is published by UCLA's Office of Intellectual Property & Industry Sponsored Research (OIP-ISR). Our monthly newsletter, subscribed to by inventors, industry and investors, highlights entrepreneurial and technology commercialization developments and opportunities at UCLA.

PLEASE ATTENTION editorial comments, corrections, and topic suggestions to:  
Bob Nidever,   bnidever@research.ucla.edu

Editor
  Bob Nidever
Contributors 
  Erin Bowers
  Neil Bajpayee

To subscribe, please visit:   http://oip.ucla.edu/UCLAinvents   

UCLA Invents
UCLA OIP-ISR
11000 Kinross Ave., Suite 200; Los Angeles, CA 90095 | tel. 310-794-0558 |  http://oip.ucla.edu

Copyright 2013 UC Regents